Absolute lymphocyte count >= 150/uL
Within 28 days of study registration: Absolute lymphocyte count (ANC) >= 4.0 x 10^8/L
Lymphocyte count > 500/uL
Lymphocyte count >= 300/uL.
Absolute lymphocyte count > 100/uL.
Patients who require immediate cytoreduction due to high risk of tumor lysis syndrome (ie, absolute lymphocyte count greater than 100k/uL)
Absolute lymphocyte count >= 1000/ul
Lymphocyte count >= 300/uL.
Absolute lymphocyte count >= 500/mm^3 obtained =< 14 days prior to registration
Within 10 days prior to on-study date: Absolute lymphocyte count ? 500/mm^3
Absolute lymphocyte count ? 400/mm^3 within 10 days prior to “on study” status
Lymphocyte count >= 300/uL
Lymphocyte count >= 300/uL
Absolute lymphocyte count >= 500/mm^3 obtained =< 14 days prior to registration
Lymphocyte count >= 300/uL
Absolute lymphocyte count ? 100/uL
Absolute lymphocyte count >= 400/uL
Absolute lymphocyte count < 500/uL
Lymphocyte count >= 300/uL
Absolute lymphocyte count ? 100/µL
Absolute lymphocyte count >= 500/ul
Absolute lymphocyte count < 200/ mm^3
ADDITIONAL CRITERIA FOR STUDY CONTINUATION: Absolute lymphocyte count >= 500/mm^3
Lymphocyte count >= 500/uL
Absolute lymphocyte count of >= 500/uL
Absolute lymphocyte count of >= 500/uL
Absolute lymphocyte count >= 500/ul (phase I only)
Absolute lymphocyte count >= 500/ul
Absolute lymphocyte count < 0.5 x 10^9/L
Absolute lymphocyte count of > 500/uL
Absolute lymphocyte count >= 500/cu mm
Within 14 days of study registration: Absolute lymphocyte count: >= 500 cells/mm^3
Absolute lymphocyte count >= 500/mm^3
Absolute lymphocyte count > 1,000/mm^3
Patients with very low CD4 counts (< 200/uL or 14% of total lymphocyte count)
Absolute lymphocyte count >= 500/mm^3
Secondary Registration: absolute lymphocyte count >= 200/uL
Lymphocyte count >= 500/uL
Absolute lymphocyte count of > 20,000 cells/ul or symptomatic splenomegaly
Absolute lymphocyte count ? 800/?L before the first dose of CG0070
Absolute lymphocyte count >= 500/uL
Absolute lymphocyte count < 0.5 x 10^9/L (Phase 1 and Phase 2 Cohort A); absolute lymphocyte count < 1.0 x 10^9/L (Phase 2 Cohort B)
Absolute lymphocyte count >= 500/ul
Absolute lymphocyte count < 800/mm^3
Absolute CD4+ lymphocyte count: >= 75 cells/uL
Absolute lymphocyte count > 500/uL
Does the subject have an absolute lymphocyte count ? 500/mm3?
Absolute lymphocyte count ?0.75 x 10^3/µl
Absolute lymphocyte count lower than 200 x 10^9/l .
absolute lymphocyte count > 500/mm^3
Absolute lymphocyte count >= 200/mm^3
Absolute lymphocyte count within institutional normal limits
Obtained within 28 days prior to registration: Absolute lymphocyte count >= 500 cells/uL
Absolute lymphocyte count ? 500/mm3
Lymphocyte count >= 500/uL
Absolute granulocyte count (AGC) >= 1,500/mm^3, within 4 weeks of randomization
Absolute granulocyte count >= 1.2 x 10^3/mm^3
Granulocyte 1500 cells/mm3
Granulocyte > 1500/ul within four weeks of enrollment
Absolute granulocyte count >= 1000 K/uL
Absolute granulocyte count >= 1,500/mm^3 (1.5 x 10^9/L)
Absolute granulocyte count >= 1,500/mcL, within 16 days of starting therapy
Granulocyte count ? 1000/mm^3
Absolute granulocyte count < 1000; platelets <100,000.
Granulocyte count >= 1000/mm3 ((within 16 days before starting therapy)
Granulocyte count >= 1000/mm^3 (within 16 days before starting therapy)
Granulocyte count <1500/mm3
Absolute granulocyte count < 1000; platelets <100,000.
Granulocyte count >= 1,500/mm^3 (within 16 days of enrollment)
Granulocyte count > 1500/mm^3
Marrow: Hemoglobin ?10.0 gm/dL, absolute granulocyte count (AGC) ?1,000/mm3 platelets ?100,000/mm3, absolute lymphocyte count ?1000/mm3.
Granulocyte count >= 1,500/mm^3
Peripheral absolute granulocyte count of > 1000/mm^3
Granulocyte count >= 1500/mm^3
A. Marrow: Hemoglobin ?10.0 gm/dL, absolute granulocyte count (AGC) ?1,000/mm3, platelets ?75,000/mm3, absolute lymphocyte count ?475/mm3.
Granulocyte count >= 1,500/mm3
Granulocyte count >= 1500/mm^3
Absolute granulocyte count (AGC) >= 1,500
Granulocyte >= 1500/ul
Absolute granulocyte count < 1,500/ul
Absolute granulocyte count < 1,500/ul
Absolute granulocyte count > 1.5 x 10^3/mm3
Absolute granulocyte count >= 1.2 x 10^3/mm^3
Granulocyte count ? 1500/mm^3 ? 2 weeks
Granulocyte >= 1,500/uL
Absolute granulocyte count >= 1.0 x 10^3/mm^3
Peripheral granulocyte count of > 1,500/mm^3
Absolute granulocyte count (AGC) >= 1,500 cells/mm^3
Granulocyte count >= 1,500/mm^3
Absolute granulocyte count >= 1,500/mm^3
Granulocyte > 1500/ul
Granulocyte count of at least 1,500/uL
Granulocyte >= 1500/ul
Granulocyte count >= 1,000/uL for lapatinib and > 1,500/uL for capecitabine
Absolute granulocyte count > 1,500/mcL
Absolute granulocyte count (AGC) >= 1,500/mm³
Granulocyte count >= 1000/mm^3 (within 16 days before starting therapy)
Peripheral granulocyte count of >= 1,500/mL
Granulocyte count >= 1,500/mm^3
Peripheral granulocyte count of >= 1500/mm³
Marrow: Hemoglobin ?10.0 gm/dL, absolute granulocyte count (AGC) ?1,000/mm3, platelets ?75,000/mm3, absolute lymphocyte count ?475/mm3.
Granulocyte count >= 1000/mm^3 (within 16 days before starting therapy)
Granulocyte count >= 1500/mm^3
Granulocyte count >= 1500/mm^3
Marrow: Hemoglobin ?10.0 dm/dL, absolute granulocyte count (AGC)?1,000/mm^3, platelets ?100,000/mm^3, absolute lymphocyte count ?1000/mm^3.
Granulocyte count >= 1000/mm^3
Absolute peripheral granulocyte count of >= 1,000/mm^3
Normal organ and marrow function as defined below: Absolute granulocyte count ? 1,500/mm3 Absolute lymphocyte count ? 500/mm3 Platelets ? 100,000/mm3 Total bilirubin ?2 mg/dL AST(SGOT)/ALT(SGPT) <2x institutional upper limit of normal Creatinine <1.5 mg/dL
Absolute granulocyte count >= 1,500/mm^3
Absolute granulocyte count >= 500/mm^3
An absolute granulocyte count > 1500/µL
Absolute granulocyte count (AGC) >= 2000 cells/mm^3
Absolute granulocyte count (ANC) >= 1.2 x 10^3/mm^3
Granulocyte count >= 1,500/mm^3 within 16 days of starting therapy
Granulocyte count >= 1,000/uL
Absolute granulocyte count >= 1.5 x 10^9/L
Granulocyte count > 1000/mm^3
Total granulocyte count of > 1500
Total granulocyte count of > 1.5 x 10^9/L
Patients should have adequate bone marrow function defined by an absolute peripheral granulocyte count of > 1,500 /mm3 and platelet count >100,000/mm3 along with an absence of a red blood cell transfusion in the two weeks prior to their participation in the trial
Platelet count (PLT) >= 100,000/uL (>= 30 X 10^9/L), within 14 days of registration
Obtained =< 21 days prior to registration: Platelet (PLT) >= 100,000/mm^3
Platelet count 100,000 (plt/mm3)
Platelet count (PLT) < 100,000/ul or
Platelet (PLT) count greater than or equal to 100,000/µL
Platelet count (PLT) > 75,000/µL
OBTAINED =< 7 DAYS PRIOR TO REGISTRATION: Platelet (PLT) >= 100,000/uL
Platelet count (PLT) > 100,000/mm^3
Platelet (PLT) > 75,000
Obtained =< 14 days prior to registration: Platelet (PLT) >= 100,000 uL
Platelet (Plt) < 120,000/mm^3
Platelet count (PLT) >= 75,000/mm^3 (measured within 28 days of registration)
Platelet (PLT) =< 100K
Platelet (PLT) count >= 100,000/mm^3
Platelet (PLT) count > 80 K/uL
Platelet count (PLT) >= 100,000/uL obtained =< 14 days prior to registration
Sufficient bone marrow capacity as defined by WBC (white blood cell ) ?2.500/?l, PLT (platelet) count ?100.000/?l, Hb?9.9 g/dl and ANC?1500 mm3 for the first cycle and WBC?2.000/ ?l,PLT count ?75.000/?l, Hb?8.9 g/dl and ANC?1000 mm3 for the subsequent cycles
Platelet count (plt) >= 100,000/ uL (obtained within 28 days prior to first study treatment)
FOR MULTIPLE MYELOMA ONLY: Obtained =< 14 days prior to registration: Platelet (PLT) >= 100,000/uL
Platelet (Plt) >= 75,000/uL
Platelet count >= 75,000 (platelets [plt]/mm^3), (CTCAE grade 1 baseline)
Platelet count (PLT) >= 75,000/uL obtained =< 14 days prior to registration
Platelet (PLT) >= 100,000/mm^3
Obtained =< 14 days prior to registration: Platelet (PLT) >= 100,000
Platelet (PLT) >= 100 K/CUMM
Within 3 months of registration: Platelet count (plt) >= 100,000/uL
Platelet count (Plt) ? 100 x 109/L
Platelet (PLT) > 99 x 10^9/L
Platelet (PLT) count >= 100,000/mm^3
Platelet (PLT) >= 75,000/uL, obtained =< 14 days prior to registration
Platelet (PLT) >= 100,000/uL (obtained =< 7 days prior to registration)
Platelet count (PLT) >= 75 x 10^9/L; PLT count less than 100 x 10^9/L if cytopenia is due to extensive bone marrow involvement of disease as determined by the treating physician
Platelet (Plt) >= 75,000
Platelet (PLT) >= 100,000/mcL
Platelet count (PLT) >= 100,000/mm^3
Platelet count >= 100,000 plt/mm^3
Platelet (PLT) >= 100,000
Platelet (PLT) count ? 100,000/µL
Platelet count (PLT) >= 100,000/mm^3
Platelet count (PLT) > 100,000/mm^3
Platelet (PLT) = 100,000/uL
Platelet count ?75,000 (plt/mm3) (CTCAE Grade 1 baseline)
Platelet count (PLT) >= 75,000 /uL without transfusions obtained =< 7 days prior to registration
Platelet (PLT) count >= 100,000/mm^3
Platelet count (PLT) >= 100,000/mm^3
Platelet (PLT) >= 100,000/mm^3
Platelet (PLT) >= 75,000/uL
Platelet (PLT) count >= 20K/uL, unless attributed to marrow infiltration with CLL
Platelet (PLT) >= 100,000/uL
Platelet count (Plt) >= 75,000/uL
Platelet (PLT) count ? 75,000/microliter
Peripheral platelet count (PLT) >= 75,000/mm^3
Peripheral platelet count (PLT) >= 100,000
Subject has a hematologic malignancy with hypoproliferative thrombocytopenia and is expected to have PLT count(s) ? 10,000/µL requiring ? 2 PLT transfusions
Platelet count (PLT) >= 100,000/mm^3
Obtained within 28 days prior to registration: Platelet count (plt) >= 100,000/uL
Platelet count (PLT) > 100 K/uL
Adequate Bone Marrow Function defined as:\r\n* Peripheral absolute phagocyte count (APC) > 1000/ µL; APC = numbers of banded neutrophils + segmented neutrophils + metamyelocytes + monocytes + eosinophils Please note, if institution reports differential as a percentage, then APC = [percentage of banded neutrophils + segmented neutrophils+ metamyelocytes+monocytes+eosinophils] x total white cell count.\r\n* Platelet Count > 100,000/µL (transfusion independent)\r\n* Hemoglobin > 8 gm/dL (may have received RBC transfusions)
Neutrophils >= 1000/uL
Neutrophils >= 1.5 x 10^9/L (for treatment phase)
Neutrophils >= 1.5 x 10^9/L
Neutrophils >= 1.5 x 10^9/L
Neutrophils >1,000 µL
Neutrophils ?1,500 ?L.
Obtained within 14 days prior to C1D1: Neutrophils >= 1500/uL
Neutrophils < 1,500 cells/µL.
Neutrophils ?1000/?L (?1 x 10^9/L)
Two out of three of the following (in peripheral blood): Neutrophils < 0.5 x10^9/L, Platelets < 20 x10^9/L, or Reticulocyte count < 20 x10^9/L
Neutrophils >= 1500
Within 14 days of the first dose of study drug: Neutrophils >= 1500/uL
Neutrophils >= 1500/uL.
Obtained within 14 days prior to randomization/registration: neutrophils >= 1500/uL
Neutrophils >= 1500/uL within 14 days of registration
Obtained within 21 days prior to randomization/registration: Neutrophils >= 1500/uL.
Absolute neutrophils > 1,500/µL
STUDY TREATMENT: Neutrophils >= 1500/ul
Neutrophils >= 1500/uL
Neutrophils >= 1500/uL
Neutrophils (Neuts) >= 1500/uL, within 30 days before study registration
Neutrophils >= 1500/uL within 14 days prior to first dose
Neutrophils >= 1500/uL
Obtained within 14 days of randomization: Neutrophils >= 1500/uL
Neutrophils < 1,500/mm^3
Neutrophils ?1.5 x 10^9/L
Neutrophils >= 1500/uL
Neutrophils >= 1500 /uL
Neutrophils >= 1.5 x 10^9 /L
Neutrophils >= 1500/uL
Absolute neutrophils >= 1500/mm^3, within 14 day prior to registration
Neutrophils >= 1500/uL obtained within 14 days prior to randomization/registration
Neutrophils >= 1500/uL
Neutrophils >= 1500/uL
Adequate hematologic function, as defined by neutrophils ? 1.0 x 10^9/L and platelets ? 50 x 10^9/L; patients with neutrophils < 1.0 x 10^9/L due to marrow infiltration are allowed to receive growth factors to bring pre-treatment neutrophils to ? 1.0 x 10^9/L.
Absolute neutrophils >= 1,500/mm^3
Absolute neutrophils >= 1500/mm^3.
Neutrophils >= 1500/uL
Absolute neutrophils > 1,500/uL
Absolute phagocyte count (APC = neutrophils and monocytes): >= 1000/mm^3
Neutrophils >= 1,500 cells/uL
Neutrophils >= 1500 cells/uL
Patients in CRi must have evidence of hematologic recovery after prior therapy to at least: absolute neutrophils >= 0.8 x 10^9/L
Neutrophils >= 1500 cells/uL
Neutrophils >= 1500/uL
Neutrophils > 1500/uL
Neutrophils >= 1500/uL
Neutrophils > 1.5 x 10^9/L
Absolute neutrophils count >= 1,500/mcL
Neutrophils >= 1.5 x 10^9 cells/L
Absolute neutrophils count >= 1500/mcl
Neutrophils > 1,000/uL prior to day 0
Neutrophils > 1000/uL
Neutrophils > 1500/uL
Neutrophils > 1000/uL
Neutrophils >= 1500/uL
Neutrophils >= 0.5 x 10^9/L, unless cytopenias are deemed due to disease
Neutrophils > 1500/uL
Neutrophils >= 1,000/ul
Neutrophils ? 1.5x109/L
Neutrophils >= 1.5 K/microliter should be obtained with 28 days prior to randomization
Neutrophils >= 1.5 x 10^9/L
Neutrophils ? 1500/µL
Neutrophils >= 1,500
Neutrophils >= 1250
Absolute Neutrophils Count (ANC) ? 1.5 x 109/L
Neutrophils > 1000/uL
Two out of three of the following (in peripheral blood): neutrophils less than 0.5 x 10^9/L; platelets less than 20 x 10^9/L; reticulocytes less than 20 x 10^9/L
Neutrophils < 1,500/µL
Neutrophils >= 1500/uL
Neutrophils < 1.5 x 10^9/L
Neutrophils >= 1000/uL, obtained within 14 days of the first dose of study drug
Neutrophils less than 1.5 x 10^9/L
Absolute Neutrophils > 1.5 x 109/L
Absolute lymphocyte count (ALC) ? 500/mm3
Absolute lymphocyte count (ALC) <400/µL.
Absolute lymphocyte count (ALC) >500/µL
Adequate organ function within 14 days of study registration including:\r\n* Absolute lymphocyte count (ALC) >= 0.5 x 10^9/L
Absolute lymphocyte count (ALC) >= 500/ mm^3
Absolute lymphocyte count (ALC) >= 100 cells/ul
PART I: Absolute lymphocyte count (ALC) >= 300 cells/mm^3
PART II: ALC >= 500 cells/mm^3
Absolute lymphocyte count (ALC) of > 5,000 K/uL
Absolute lymphocyte count (ALC) ? 300/mm^3, and absolute number of CD3+ T cells > 150/mm^3
Absolute blood lymphocyte (ALC) >= 100 cells/ul\r\n* If subject has an apheresis product or T cells available for manufacturing of T cell product, there is no minimum ALC requirement
Absolute blood lymphocyte (ALC) >= 100 cells/ul\r\n* If subject has an apheresis product or T cells available for manufacturing of T cell product, there is no minimum ALC requirement
Absolute lymphocyte count (ALC) >= 0.8 x 10^9/L.
Absolute lymphocyte count (ALC) >1000 cells/mm3
Absolute lymphocyte count (ALC) >= 500/mm^3
Patient must have no persistent toxicities from prior therapy >= grade 2 with the exception of\r\nhematologic indices (i.e., hemoglobin, white blood cell count [WBC], ANC, absolute lymphocyte count [ALC])
Absolute lymphocyte count (ALC) >= 500/uL
Absolute lymphocyte count (ALC) >= 100 cells/ul
Absolute lymphocyte count (ALC) > 500
Patients must have absolute lymphocyte counts (ALC) of more than 5,000 cell/mm^3
Absolute lymphocyte count (ALC) > 800/ul
Absolute lymphocyte count (ALC) >= 500/mm^3
Absolute lymphocyte count (ALC) >= 800/uL
Absolute lymphocyte count (ALC) ? 300/mm3
Progressive lymphocytosis in the absence of infection, with an increase in blood Absolute Lymphocyte Count (ALC) >=50% over a 2-month period, or a lymphocyte doubling time (LDT) of <6 months (as long as initial ALC was >=30000/µl).
either ALC >10 000/µL, or
Absolute lymphocyte count (ALC) ? 1 × 10e3/µL
Patients with a diagnosis of CLL (any stage) with absolute lymphocyte count (ALC) >= 20 x 109/l, requiring therapy
Absolute lymphocyte count (ALC) >= 250/uL obtained =< 7 days prior to registration
For Phase 1b individuals: absolute lymphocyte count (ALC) > 5000/?L in peripheral blood.
Absolute lymphocyte count (ALC) >= 0.5 X 10^9/L
Absolute lymphocyte count (ALC) >= 200/?L
ALC >100/uL
Absolute lymphocyte count (ALC) ? 1,000/?l (? 500/?l after stem cell transplant) Note: After completion of dose escalation, patients with AML are not required to meet these hematologic criteria.
REGISTRATION STEP 2-RANDOMIZATION: The following tests must be performed within 14 days prior to randomization (registration to Step 2) to establish baseline values:\r\n* Performance status\r\n* Complete blood count (CBC)/differential/platelets\r\n* Creatinine clearance (Cockcroft-Gault)\r\n* Total bilirubin\r\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)\r\n* Lactate dehydrogenase (LDH)\r\n* Albumin\r\n* Glucose\r\n* Fibrinogen\r\n* Electrocardiogram (ECG)
Complete blood count (CBC)/differential obtained within 28 days prior to step 2 registration
Blood cell count (CBC)/differential obtained within 60 days prior to registration on study
Prestudy history and physical must be obtained within 90 days prior to registration; patients must have a complete blood count (CBC) and basic metabolic panel including creatinine, potassium, chloride, blood urea nitrogen (BUN), carbon dioxide (CO2) and glucose within 28 days prior to registration
The following laboratory values obtained =< 21 days prior to registration; complete blood count (CBC), sodium, potassium, aspartate aminotransferase (AST), bilirubin and creatinine are to be obtained pre-study; Note: treatment initiation and dosing modification should be performed at the individual investigators discretion and be consistent with the product label and their medical practice
Blood cell count (CBC)/differential obtained within 8 weeks prior to registration on study
Absolute neutrophil count >= 1,500 cells/mm^3 based on complete blood count (CBC)/differential within 14 days prior to Step 2 registration
Platelet count >= 100,000 cells/mm^3 based on CBC/differential within 14 days prior to Step 2 registration
Hemoglobin > 9.0 g/dl (may be transfused to achieve this level) based on CBC/differential within 14 days prior to Step 2 registration
Patients must not have metastatic disease on staging work-up with blood cell count (CBC) and liver function studies
No evidence of recurrent local or distant breast cancer by physical examination, blood tests (complete blood count [CBC], liver function tests [LFTs], alkaline phosphatase [alk phos]), or symptom-directed imaging, per National Comprehensive Cancer Network (NCCN) guidelines
DONOR: Complete blood count (CBC) with differential and platelet count within normal limits, as deemed acceptable by the principal investigator
Complete blood count (CBC)/differential obtained within 7 days prior to starting the study drug with adequate bone marrow function, defined as follows:
Microcytosis on screening blood cell count (CBC) (mean corpuscular volume [MCV] < 81 fL)
Complete blood count (CBC) - no clinically significant findings
Complete blood count (CBC) with differential and a comprehensive metabolic panel (CMP) including liver function tests (LFTs) obtained within 14 days prior to registration
A complete blood count and differential must be obtained within 21 days prior to radiation fraction 1
DONOR: Complete blood count (CBC) within one week of donation; results of tests must be within a range that would not preclude donating blood or undergoing leukapheresis
Complete blood count/differential at screening with adequate bone marrow function
Complete blood count (CBC)/differential obtained no more than 4 weeks prior to registration on study, with adequate bone marrow function
Complete blood count, differential and platelet count must be within normal limits (WNL) or verified by the study chair to be related to conditions not interfering with normal health status
Complete blood count (CBC)/differential obtained within 21 days of registration on study (or within 21 days prior to day 1 of chemotherapy post-surgery for those patients having started chemotherapy prior to first step registration)
Complete blood count (CBC)/differential obtained within 30 days prior to registration on study, with adequate bone marrow function
Complete blood count (CBC) without clinically significant abnormalities after review by the study physicians
For patients undergoing brachytherapy only: complete blood count (CBC)/differential obtained within 60 days prior to registration, with adequate bone marrow function defined as follows:
Absolute neutrophil count (ANC) >= 1500 cells/mm^3 based on complete blood count (CBC)/differential obtained within 21 days prior to study registration
Platelets >= 100,000 cells/mm^3 based on CBC/differential obtained within 21 days prior to study registration
Complete blood count (CBC)/differential obtained within 14 days prior to registration, with adequate bone marrow function
DONOR: Complete blood count (CBC)/diff/platelet count near normal limits (+/- 10%)
Hemoglobin > 8.0 g/dl based upon complete blood count (CBC)/differential obtained within 2 weeks prior to registration on study
DONOR: Complete blood count (CBC)/diff/platelet count near normal limits (plus/minus 10%)
Patients must have adequate organ function, defined as (Note: Complete Blood Count (CBC) test should be obtained without transfusion or receipt of stimulating factors within 2 weeks before obtaining screening blood sample):
Adequate organ function, defined as (Note: CBC test should be obtained without transfusion or receipt of colony stimulating factors within 2 weeks before obtaining sample):
Complete blood count (CBC), differential and platelet count
Acceptable hemoglobin and hematocrit level based on complete blood count (CBC)
Subject has no access to a telephone. 18. Subject has no documented blood values (complete blood count [CBC], coagulation tests, urea and electrolytes, and liver function tests [LFTs]) within the last 10 days.
Patient or legal representative must agree to blood serum assessment including, complete blood count (CBC) with differential, comprehensive metabolic panel and serum osmolality at every sanctioned evaluation; additionally physician may require cardiac evaluation with echocardiogram, electrocardiogram, brain naturetic peptide or urinalysis if deemed appropriate
A complete blood count (CBC) and chemistry profile (Cohort A2), must have been performed after completion of any breast cancer surgery, radiation therapy, or cytotoxic chemotherapy, with reasonably normal liver and renal function as well as a hemoglobin of 10 or higher and/or performed within a year of study entry
A complete blood count (CBC) and chemistry profile, must have been performed after completion of any breast cancer surgery, radiation therapy, or cytotoxic chemotherapy, with reasonably normal liver and renal function and a hemoglobin of 10 or higher
Have reasonable organ function as documented by complete blood count (CBC) and metabolic chemistry profile (within 3 months prior to study entry visit)
Screening laboratory values (comprehensive metabolic panel, complete blood count [CBC], complete urinalysis, a urinary drug screen, and, if applicable, FSH) within institutional normal range or judged to be not clinically significant by the site principal investigator (PI) and medical monitor
Complete blood count (CBC) including diff & platelets - without clinically significant abnormalities
CBC (complete blood count) without clinically significant abnormalities after review by the study physicians
Although not mandated by the protocol, the results of the computed tomography (CT) scans and labs (complete blood count [CBC], comprehensive metabolic panel [CMP]) that are performed as part of the standard work up should be available and should have been done within 2 months prior to study entry
Complete blood count (CBC) with platelets less than 4.0 times below or above the upper or lower limit range
Physical exam, complete blood count (CBC) and multiphasic (including electrolytes, blood urea nitrogen [BUN], creatinine, total bilirubin, aspartate aminotransferase [AST], and alanine aminotransferase [ALT]) must be done within 28 days of PET imaging, but eligibility is not restricted by these results; the CBC and multiphasic may be drawn at the time of imaging
Complete blood count (CBC) with platelets less than 4.0 times below or above the upper or lower limit range
Note: Complete blood count (CBC) and differential should be reported for the phenotyped sample.
STUDY TREATMENT: Lymphocyte count >= 300/uL within 14 days prior to the first study treatment.
Obtained within 14 days of the first study treatment: Lymphocyte count > 500/uL
Obtained within 14 days of the first study treatment: Lymphocyte count >500/uL
Obtained within 14 days prior to the first study treatment (cycle 1, day 1): lymphocyte count >= 500/uL
Obtained within 14 days prior to the first study treatment (cycle 1, day 1): platelet count >= 100,000/uL
Within 14 days prior to cycle 1 day 1 of treatment: Absolute lymphocyte count >= 500/uL
Within 14 days prior to cycle 1 day 1 of treatment: Platelet count >= 100,000/uL
Within 14 days prior to the first study treatment (cycle 1, day 1): Lymphocyte count >= 300/uL
Absolute lymphocyte count >= 500 cells/uL (obtained within 28 days prior to first study treatment)
Lymphocyte count ? 300/uL within 14 days prior to the first study treatment (cycle 1, day 1)
Platelet count ? 100,000/uL within 14 days prior to the first study treatment (cycle 1, day 1)
Within 14 days prior to the first study treatment (cycle 1, day 1): Lymphocyte count >= 300/uL.
Absolute neutrophil count >= 1500 cells/uL, obtained within 14 days prior to the first study treatment (cycle 1, day 1)
Lymphocyte count >= 300/uL, obtained within 14 days prior to the first study treatment (cycle 1, day 1)
Platelet count >= 100,000/uL, obtained within 14 days prior to the first study treatment (cycle 1, day 1)
Lymphocyte count >= 0.5 x 10^9/L, obtained within 14 days prior to initiation of study treatment
Within 14 days prior to the first study treatment (cycle 1, day 1): Lymphocyte count >= 500/uL
Obtained within 14 days prior to the first study treatment (cycle 1, day 1); lymphocyte count ? 300/uL
Obtained within 14 days prior to the first study treatment (cycle 1, day 1); platelet count ? 75,000/uL
Lymphocyte count >= 300/uL (obtained within 14 days prior to the first study treatment [course 1, day 1])
Platelet count >= 75 x 10^3/uL obtained at baseline (day 1 of cycle 1, before study drug administration)
Absolute neutrophil count >= 1.0 x 10^3/uL obtained at baseline (day 1 of cycle 1, before study drug administration)
Lymphocyte count >= 500/uL (obtained within 28 days prior to the first study treatment)
Total lymphocyte count >= 0.5 x 10^9/L
Absolute lymphocyte count > 500/ mcL
Patients with a peripheral blood total lymphocyte count of higher than 25,000/mm3 may not be enrolled.
Absolute lymphocyte count >= 500/mcL, within 16 days of starting therapy
CD4 lymphocyte count or other T lymphocyte subset count will not be used to determine eligibility
Lymphocyte count >= 0.5 × 10^9/L.
Lymphocyte count >= 0.5 x 10^9/L
Lymphocyte count >= 0.5 x 10^9/L (in absence of blood transfusion).
Absolute lymphocyte count >= 800/mcL
Lymphocyte count > 1,000/mcL
Within 30 days of first vaccination: Lymphocyte count >= 800/mm^3
Absolute lymphocyte count >= 500/mcl
Lymphocyte count ? 0.5 x 109/L (500/µL)
Lymphocyte count >= 400/mm^3
Absolute lymphocyte count >= 800/mcL
Lymphocyte count ? 500/mm3
Lymphocyte count ? 300/µL
Within 14 days of enrollment: Lymphocyte count >= 300/mm^3
Lymphocyte count >= 400/mm^3
Lymphocyte count greater than or equal to 700/mcL
Lymphocyte count less than or equal to 4,000/mm^3
Lymphocyte count 500/mL
Lymphocyte count >= 300/mcL
Lymphocyte count <1000/µL,
Lymphocyte count ? 0.8 x 103 cells/µL
Lymphocyte count ? 500/mm3
CD4 lymphocyte count is highly encouraged
Absolute lymphocyte count >= 500/mcL
Patients must have normal bone marrow function, with a baseline total lymphocyte count >= 1000
Lymphocyte count >= 800/mm^3 within 90 days of enrollment